CVD in American Indians Study and Data Management Center and OK Field Center

美洲印第安人CVD研究与数据管理中心和OK现场中心

基本信息

批准号：
8846648
负责人：
ELISA TAN LEE
金额：
$ 88.41万
依托单位：
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-06-01 至 2016-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8846648
关键词：
Abdomen Address Adipose tissue Adult Affect Age Alcohols Algorithms Alleles American Indians Architecture Atrial Fibrillation Behavioral Biological Blood Pressure Caliber Cardiac Cardiovascular Diseases Cardiovascular Physiology Clinical Cohort Studies Coupled Data Deposition Diabetes Mellitus Diet Disease Drug or chemical Tissue Distribution Elderly Environmental Exposure Epidemic Etiology Event Extended Family Family Family Study Fatty acid glycerol esters Foundations Functional disorder Gene Expression Genes Genetic Genetic Determinism Genetic Markers Genetic Predisposition to Disease Genetic Variation Genomics Health Heart Heart failure Hepatic Individual Inflammation Insulin Resistance Investigation Kidney Diseases Knowledge Lead Life Expectancy Link Liver Magnetic Resonance Imaging Measurement Measures Mental Health Metabolic Morbidity - disease rate Myocardial Infarction Nonesterified Fatty Acids Obesity Participant Persons Phenotype Physical activity Physiological Placebo Effect Plant Roots Population Prevention therapy Process RNA Recurrence Reproductive History Resources Risk Factors Role Socioeconomic Status Solid Staging Stroke Techniques Technology Tobacco use Triglycerides Variant abdominal fat aged base behavior measurement cardiovascular disorder risk clinical practice cohort data management demographics design diabetic diabetic cardiomyopathy experience follow-up genetic analysis genetic variant health disparity heart rate variability inflammatory marker information gathering innovation insight interest member middle age mortality novel obesity risk pre-clinical surveillance data tonometry transcriptomics trend

Abdomen Address Adipose tissue Adult Affect Age Alcohols Algorithms Alleles American Indians Architecture Atrial Fibrillation Behavioral Biological Blood Pressure Caliber Cardiac Cardiovascular Diseases Cardiovascular Physiology Clinical Cohort Studies Coupled Data Deposition Diabetes Mellitus Diet Disease Drug or chemical Tissue Distribution Elderly Environmental Exposure Epidemic Etiology Event Extended Family Family Family Study Fatty acid glycerol esters Foundations Functional disorder Gene Expression Genes Genetic Genetic Determinism Genetic Markers Genetic Predisposition to Disease Genetic Variation Genomics Health Heart Heart failure Hepatic Individual Inflammation Insulin Resistance Investigation Kidney Diseases Knowledge Lead Life Expectancy Link Liver Magnetic Resonance Imaging Measurement Measures Mental Health Metabolic Morbidity - disease rate Myocardial Infarction Nonesterified Fatty Acids Obesity Participant Persons Phenotype Physical activity Physiological Placebo Effect Plant Roots Population Prevention therapy Process RNA Recurrence Reproductive History Resources Risk Factors Role Socioeconomic Status Solid Staging Stroke Techniques Technology Tobacco use Triglycerides Variant abdominal fat aged base behavior measurement cardiovascular disorder risk clinical practice cohort data management demographics design diabetic diabetic cardiomyopathy experience follow-up genetic analysis genetic variant health disparity heart rate variability inflammatory marker information gathering innovation insight interest member middle age mortality novel obesity risk pre-clinical surveillance data tonometry transcriptomics trend

展开

项目摘要

DESCRIPTION (provided by applicant): The Strong Heart Study (SHS) of two unique American Indian (AI) cohorts (4549 adults, aged 45 to 74 and 3838 ¿15 yrs. from 94 families) constitutes an unequalled and irreplaceable national resource. The proposed studies will elucidate the genetics and early pathophysiology of diabetic CVD and also address health disparities experienced by populations with high rates of diabetes and CVD. Very high rates of obesity and diabetes, especially among younger SHS participants, herald a pending epidemic of CVD, making them the ideal population in which to examine these processes. Measures of CVD, preclinical CVD, biomarkers, and genetic findings have provided valuable pathogenetic insights related to the etiology of CVD; the proposed investigations will take maximal advantage of this solid foundation and add innovative new measures. Our Aims: The identification of genetic variants affecting risk of obesity, diabetes, preclinical CVD, and CVD events, aided by new genomic technologies. We will use genomics techniques for SNP discovery and subsequent statistical analysis of functionality in regions known to contain genes of interest. Transcriptional profiling of RNA concurrent with a liver/abdominal MRI will be used to relate expression of genes and gene networks to CVD etiology. New biological measurements during a re-examination of the large family-based cohort will expand knowledge of pre-clinical stages of obesity and diabetes associated CVD. Novel phenotypes defined by MRI of the abdomen (for fat deposition in liver and adipose depots) will elucidate the etiology of preclinical disease in younger persons. Measures of central blood pressure (by applanation tonometry), heart rate variability and abdominal aortic size will broaden our understanding of CVD in association with obesity and diabetes. Measures of physiologic and behavioral risk factors, such as demographics, reproductive history, socioeconomic status, tobacco use, alcohol, diet, mental health indicators, and physical activity (by accelerometer) will add additional key phenotypes. Continuing mortality and morbidity surveillance of these cohorts will provide increased power in understanding how obesity and diabetes lead to strokes and heart failure in later life. Secular trends, life expectancy, the effects of renal disease on preclinical CVD, and the role of preclinical measures in predicting CVD endpoints will be explored. Thus, the proposed investigations will lead to new understanding of CVD and preclinical and diabetic CVD as well as improvements in clinical practice.

描述（由适用提供）：两个独特的美洲印第安人（AI）队列（4549名成年人，45至74至74岁和3838年）的强大心脏研究（SHS）构成了一种不平等且不可替代的国家资源。拟议的研究将阐明糖尿病CVD的遗传学和早期病理生理学，并解决糖尿病和CVD率高的人群所经历的健康差异。肥胖和糖尿病的率很高，尤其是在年轻的SHS参与者中，预示了CVD的待处理流行，使其成为检查这些过程的理想人群。 CVD，临床前CVD，生物标志物和遗传发现的度量已提供了与CVD病因相关的有价值的致病见解。拟议的调查将最大程度地利用这一扎实的基础，并增加创新的新测量。我们的目的是：鉴定影响观察风险，糖尿病，临床前CVD和CVD事件的遗传变异，并在新的基因组技术的帮助下。我们将使用基因组技术进行SNP发现和随后在已知包含感兴趣基因的地区功能的统计分析。 RNA与肝脏/腹部MRI并发的转录分析将用于将基因和基因网络的表达与CVD病因联系起来。重新检查大型家庭队列期间的新生物学测量将扩大对肥胖和糖尿病相关CVD的临床前阶段的了解。腹部MRI定义的新表型（对于肝脏和脂肪沉积物中的脂肪沉积）将阐明年轻人的临床前疾病的病因。中枢血压力（按应用传动力计），心率变异性和腹主动脉尺寸的度量将扩大我们与肥胖和糖尿病相关的CVD的理解。身体和行为危险因素的度量，例如人口统计学，生殖历史，社会经济状况，烟草使用，酒精，饮食，心理健康指标和体育活动（通过加速度计）将增加其他关键表型。这些队列的持续死亡率和发病率监视将提供更多的力量，以了解肥胖和糖尿病如何导致后来的中风和心力衰竭。世俗趋势，预期寿命，肾脏疾病对临床前CVD的影响以及临床前测量在预测CVD终点方面的作用。这是拟议的研究将导致对CVD以及临床前和糖尿病CVD的新了解，以及临床实践的改善。